Recent clinical trials utilizing intravascular ultrasound (IVUS) to quantify coronary artery plaque burden have demonstrated that statin therapy has the potential to arrest the progression of coronary artery disease, and even to effect a small amount of plaque regression. Rosuvastatin is more effective than atorvastatin in reducing low-density lipoprotein (LDL) and increasing high-density lipoprotein (HDL) levels. Whether this translates into more effective plaque regression is not known. Accordingly, Nicholls and colleagues performed a large, multicenter clinical trial to compare the effects of high-dose atorvastatin vs high-dose rosuvastatin on coronary artery plaque burden.